Merus (NASDAQ:MRUS) Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its position in shares of Merus (NASDAQ:MRUS - Free Report) by 1.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,031,827 shares of the biotechnology company's stock after purchasing an additional 19,379 shares during the period. Pictet Asset Management Holding SA owned 1.51% of Merus worth $43,388,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Avior Wealth Management LLC acquired a new stake in Merus during the fourth quarter worth approximately $76,000. MML Investors Services LLC purchased a new position in shares of Merus during the 3rd quarter worth $206,000. Gordian Capital Singapore Pte Ltd boosted its holdings in shares of Merus by 10.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock worth $250,000 after purchasing an additional 470 shares during the last quarter. HighTower Advisors LLC grew its position in shares of Merus by 10.9% in the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock valued at $337,000 after purchasing an additional 789 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Merus in the fourth quarter valued at $347,000. 96.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on MRUS. Guggenheim reissued a "buy" rating and issued a $109.00 price target on shares of Merus in a research note on Friday, March 28th. William Blair restated an "outperform" rating on shares of Merus in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target on shares of Merus in a research report on Monday, March 3rd. Piper Sandler began coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price target on the stock. Finally, Citigroup upped their price objective on Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $85.31.

Remove Ads

Merus Stock Down 8.7 %

Shares of Merus stock traded down $3.62 during trading hours on Friday, hitting $38.11. 1,233,383 shares of the company's stock traded hands, compared to its average volume of 704,078. Merus has a twelve month low of $36.46 and a twelve month high of $61.61. The company has a market cap of $2.63 billion, a PE ratio of -9.65 and a beta of 1.02. The stock has a 50 day simple moving average of $44.02 and a 200-day simple moving average of $45.77.

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million for the quarter, compared to the consensus estimate of $10.57 million. As a group, equities research analysts predict that Merus will post -3.85 EPS for the current year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.